MTA-induced protein methyltransferase (PRMT) inhibition and lack of symmetric dimethyl arginine (SDMA) activity in MTAP-null lung cancers leads to reduced degradation of vimentin and increased metastatic activity [67]. The gene discussed is MTAP; the disease is lung cancer.